Skip to main content
. Author manuscript; available in PMC: 2009 Dec 28.
Published in final edited form as: Eur J Pharmacol. 2008 Oct 21;601(1-3):207–208. doi: 10.1016/j.ejphar.2008.10.033

Fig 1.

Fig 1

A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of i-Fect encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting dsRNA (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.